Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of general internal medicine

• Publication date

  2011-01-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11606-010-1569-5PMID 21203860PMCID PMC3043173
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program.

  2010cited by this paper
• AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program.

  2010cited by this paper
• AHRQ series paper 2: principles for developing guidance: AHRQ and the effective health-care program.

  2010cited by this paper
• Side effects of long‐term oral antiviral therapy for hepatitis B

  2009cited by this paper
• Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence

  2009cited by this paper
• Antiviral resistance and hepatitis B therapy

  2009cited by this paper
• Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B

  2009cited by this paper
• Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference

  2009cited by this paper
• ACP Journal Club. Review: evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B.

  2009cited by this paper
• Reactivation of hepatitis B

  2009cited by this paper
• Comparative Effectiveness Research: A Report From the Institute of Medicine

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cited by this paper
• Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data

  2009cited by this paper
• Cost-effectiveness of oral treatments for chronic hepatitis B.

  2009cited by this paper
• Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

  2009cited by this paper
• Benefits and risks of interferon therapy for hepatitis B

  2009cited by this paper
• National Institutes of Health consensus development conference statement: Management of hepatitis B

  2009cited by this paper
• Hepatitis B virus DNA levels and outcomes in chronic hepatitis B

  2009cited by this paper
• Endpoints of therapy in chronic hepatitis B

  2009cited by this paper
• Benefits and risks of nucleoside analog therapy for hepatitis B

  2009cited by this paper
• Pharmacoeconomics of entecavir treatment for chronic hepatitis B

  2008cited by this paper
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

  2008cited by this paper
• Management of chronic hepatitis B

  2008cited by this paper
• NIH consensus development statement on management of hepatitis B.

  2008cited by this paper
• Management of chronic hepatitis B.

  2008cited by this paper
• Confidence intervals for the amount of heterogeneity in meta‐analysis

  2007cited by this paper
• Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis

  2007cited by this paper
• Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy.

  2007cited by this paper
• Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

  2007cited by this paper
• [Not Available].

  2007cited by this paper
• Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.

  2007cited by this paper
• Natural history of hepatitis B virus infection: an update for clinicians.

  2007cited by this paper
• Hepatic Steatosis has no Impact on the Outcome of Treatment in Patients With Chronic Hepatitis B Infection

  2007cited by this paper
• Adefovir Dipivoxil Alone or in Combination with Lamivudine for Three Months in Patients with Lamivudine Resistant Compensated Chronic Hepatitis B

  2007cited by this paper
• Guidelines for the diagnosis of uncomplicated cirrhosis.

  2007cited by this paper
• Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double‐blind trial

  2007cited by this paper
• Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.

  2007cited by this paper
• Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients.

  2007cited by this paper
• Telbivudine versus lamivudine in patients with chronic hepatitis B.

  2007cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

  2006cited by this paper
• Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.

  2006cited by this paper
• Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype

  2006cited by this paper
• Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response

  2006cited by this paper
• Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine

  2006cited by this paper
• Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment.

  2006cited by this paper
• Peg‐interferon improves liver histology in patients with HBeAg‐positive chronic hepatitis B: no additional benefit of combination with lamivudine

  2006cited by this paper
• Genetic polymorphisms of interleukin‐1‐beta in association with sustained response to anti‐viral treatment in chronic hepatitis B in Chinese

  2006cited by this paper
• Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant.

  2006cited by this paper
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

  2006cited by this paper
• Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.

  2006cited by this paper
• Two-year Lamivudine treatment for Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial

  2006cited by this paper
• High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study

  2006cited by this paper
• A double‐blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg‐positive chronic hepatitis B

  2006cited by this paper
• Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• Assessing the Amount of Heterogeneity in Random‐Effects Meta‐Analysis

  2006cited by this paper
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

  2005cited by this paper
• Systems for grading the quality of evidence and the strength of recommendations II: Pilot study of a new system

  2005cited by this paper
• The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

  2005cited by this paper
• Higher Efficacy of Sequential Therapy with Interferon-α and Lamivudine Combination Compared to Lamivudine Monotherapy in HBeAg Positive Chronic Hepatitis B Patients

  2005cited by this paper
• Long‐term follow‐up of peginterferon and lamivudine combination treatment in HBeAg‐positive chronic hepatitis B

  2005cited by this paper
• Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy

  2005cited by this paper
• A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.

  2005cited by this paper
• Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.

  2005cited by this paper
• A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.

  2005cited by this paper
• A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone

  2005cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy

  2005cited by this paper
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

  2005cited by this paper
• A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

  2005cited by this paper
• Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

  2005cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Combination of α‐interferon with lamivudine reduces viral breakthrough during long‐term therapy

  2004cited by this paper
• Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy.

  2004cited by this paper
• Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.

  2004cited by this paper
• Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

  2004cited by this paper
• Well informed uncertainties about the effects of treatments

  2004cited by this paper
• Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group

  2004cited by this paper
• Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.

  2004cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004cited by this paper
• Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.

  2003cited by this paper
• Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil

  2003cited by this paper
• Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

  2003cited by this paper
• Comparison of 12-Month Courses of Interferon-α-2b–Lamivudine Combination Therapy and Interferon-α-2b Monotherapy among Patients with Untreated Chronic Hepatitis B

  2003cited by this paper
• Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

  2003cited by this paper
• Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

  2003cited by this paper
• Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

  2003cited by this paper
• Interferon–Lamivudine Combination is No Better than Lamivudine Alone in Anti-Hbe-Positive Chronic Hepatitis B

  2003cited by this paper
• Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Systems to rate the strength of scientific evidence.

  2002cited by this paper
• Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

  2002cited by this paper
• HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

  2002cited by this paper
• Meta-Analysis of Controlled Clinical Trials

  2002cited by this paper
• Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

  2002cited by this paper
• Current methods of the US Preventive Services Task Force: a review of the process.

  2001cited by this paper
• Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.

  2001cited by this paper

• “Elimination of Hepatitis by 2030”: Present Realities and Future Projections

  2021cites this paper
• Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical

  2021cites this paper
• Benefit-risk assessment of medicines: a contribution for evidence-based decisions using the number needed to treat to benefit or to harm

  2017cites this paper
• Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.

  2016cites this paper
• A Nanoscale Mutation-Sensitive On/Off Switch Based Assays for the Detection of Hepatitis B Virus Lamivudine-Resistant Mutations.

  2015cites this paper
• Hepatitis B and D Viruses

  2015cites this paper
• ДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОФИЛАКТИКА ХРОНИЧЕСКОГО ГЕПАТИТА B С ПОЗИЦИИ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ © Лапасов С.Х., Хакимова Л.Р., Аблакулова М.Х., Валиева М.Х. Кафедра по повышению квалификации и переподготовке врачей общей практики факультета усовершенствования врачей Самаркандского государственного меди

  2015cites this paper
• Management of chronic hepatitis B in children: An unresolved issue

  2014cites this paper
• Screening for Hepatitis B Virus Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

  2014cites this paper
• Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation

  2014cites this paper
• Article Commentary: What Evidence Exists to Support Antiviral Treatment in Children with Chronic Hepatitis B?

  2014influential citation
• Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice

  2013cites this paper
• PREVALÊNCIA DE MUTAÇÕES ASSOCIADAS AO DESENVOLVIMENTO DE RESISTÊNCIA À LAMIVUDINA EM PACIENTES COM HEPATITE B CRÔNICA DO MUNICÍPIO DE BENTO GONÇALVES, RS

  2012cites this paper
• Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy

  2012cites this paper
• Hepatitis B virus management to prevent reactivation after chemotherapy: a review

  2012cites this paper
• Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients

  2012cites this paper
• Clinical evidence for the regression of liver fibrosis.

  2012cites this paper
• Hepatitis B—More Treatments, More Testing, Not Enough Data

  2011cites this paper
• Recent advances in the treatment of chronic hepatitis B

  2011cites this paper